IMVT financials
Immunovant (IMVT) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
IMVT income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2026 | $0.00 | -$409.00K | -$532.90M | -$505.61M | -2.77 |
| 2025 | $0.00 | $0.00 | -$438.15M | -$413.84M | -2.73 |
| 2024 | $0.00 | $0.00 | -$270.21M | -$259.34M | -1.88 |
| 2023 | $0.00 | $0.00 | -$208.28M | -$210.96M | -1.71 |
| 2022 | $0.00 | $0.00 | -$156.03M | -$156.73M | -1.43 |
| 2021 | $0.00 | $0.00 | -$108.12M | -$107.43M | -1.22 |